NO322450B1 - Blanding for regulering av celleproliferasjon og celledod samt anvendelse derav - Google Patents

Blanding for regulering av celleproliferasjon og celledod samt anvendelse derav Download PDF

Info

Publication number: NO322450B1
Authority: NO; Norway
Prior art keywords: dna; mcc; cells; cancer; phlei
Prior art date: 1997-08-05

Application number

NO20000576A

Other languages

English (en)

Norwegian (no)

Other versions

NO20000576D0 (no

NO20000576L (no

Inventor

Nigel C Phillips

Mario C Filion

Original Assignee

Bioniche Life Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-05

Filing date

2000-02-04

Publication date

2006-10-09

2000-02-04 Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc

2000-02-04 Publication of NO20000576D0 publication Critical patent/NO20000576D0/no

2000-04-04 Publication of NO20000576L publication Critical patent/NO20000576L/no

2006-10-09 Publication of NO322450B1 publication Critical patent/NO322450B1/no

Links

239000000203 mixture Substances 0.000 title claims abstract description 76
230000025053 regulation of cell proliferation Effects 0.000 title description 2
230000020129 regulation of cell death Effects 0.000 title 1
210000004027 cell Anatomy 0.000 claims abstract description 168
241000187481 Mycobacterium phlei Species 0.000 claims abstract description 83
230000000694 effects Effects 0.000 claims abstract description 45
210000002421 cell wall Anatomy 0.000 claims abstract description 35
241001465754 Metazoa Species 0.000 claims abstract description 14
229940055036 mycobacterium phlei Drugs 0.000 claims abstract description 7
206010028980 Neoplasm Diseases 0.000 claims description 81
201000011510 cancer Diseases 0.000 claims description 69
210000001616 monocyte Anatomy 0.000 claims description 56
238000011282 treatment Methods 0.000 claims description 35
239000003937 drug carrier Substances 0.000 claims description 34
230000035755 proliferation Effects 0.000 claims description 30
230000000638 stimulation Effects 0.000 claims description 28
230000001093 anti-cancer Effects 0.000 claims description 27
238000004519 manufacturing process Methods 0.000 claims description 27
102000013462 Interleukin-12 Human genes 0.000 claims description 26
108010065805 Interleukin-12 Proteins 0.000 claims description 26
210000002540 macrophage Anatomy 0.000 claims description 22
239000008365 aqueous carrier Substances 0.000 claims description 21
230000006882 induction of apoptosis Effects 0.000 claims description 19
210000000987 immune system Anatomy 0.000 claims description 17
102000004889 Interleukin-6 Human genes 0.000 claims description 14
108090001005 Interleukin-6 Proteins 0.000 claims description 14
230000005764 inhibitory process Effects 0.000 claims description 14
102000003952 Caspase 3 Human genes 0.000 claims description 12
108090000397 Caspase 3 Proteins 0.000 claims description 12
102000004127 Cytokines Human genes 0.000 claims description 12
108090000695 Cytokines Proteins 0.000 claims description 12
230000006698 induction Effects 0.000 claims description 12
102000003814 Interleukin-10 Human genes 0.000 claims description 10
108090000174 Interleukin-10 Proteins 0.000 claims description 10
239000003642 reactive oxygen metabolite Substances 0.000 claims description 8
206010059866 Drug resistance Diseases 0.000 claims description 5
230000016396 cytokine production Effects 0.000 claims description 4
230000016412 positive regulation of cytokine production Effects 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 2
238000000034 method Methods 0.000 abstract description 13
230000004044 response Effects 0.000 abstract description 7
230000001939 inductive effect Effects 0.000 abstract description 6
102000011727 Caspases Human genes 0.000 abstract description 3
108010076667 Caspases Proteins 0.000 abstract description 3
108020004414 DNA Proteins 0.000 description 142
102000053602 DNA Human genes 0.000 description 142
102000007260 Deoxyribonuclease I Human genes 0.000 description 45
108010008532 Deoxyribonuclease I Proteins 0.000 description 45
230000006907 apoptotic process Effects 0.000 description 45
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 38
230000019734 interleukin-12 production Effects 0.000 description 35
241001529936 Murinae Species 0.000 description 25
229940117681 interleukin-12 Drugs 0.000 description 23
239000000969 carrier Substances 0.000 description 22
241000699670 Mus sp. Species 0.000 description 18
208000032839 leukemia Diseases 0.000 description 18
206010005003 Bladder cancer Diseases 0.000 description 17
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 17
201000005112 urinary bladder cancer Diseases 0.000 description 17
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
229940094991 herring sperm dna Drugs 0.000 description 16
239000000725 suspension Substances 0.000 description 16
238000002360 preparation method Methods 0.000 description 15
108091034117 Oligonucleotide Proteins 0.000 description 14
238000013467 fragmentation Methods 0.000 description 14
238000006062 fragmentation reaction Methods 0.000 description 14
241001467552 Mycobacterium bovis BCG Species 0.000 description 13
238000002474 experimental method Methods 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
238000002347 injection Methods 0.000 description 12
239000007924 injection Substances 0.000 description 12
101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 11
101150064015 FAS gene Proteins 0.000 description 11
101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 11
229940100601 interleukin-6 Drugs 0.000 description 11
239000002609 medium Substances 0.000 description 11
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 10
239000003814 drug Substances 0.000 description 10
239000011780 sodium chloride Substances 0.000 description 10
239000007787 solid Substances 0.000 description 10
239000002246 antineoplastic agent Substances 0.000 description 9
230000001580 bacterial effect Effects 0.000 description 9
239000002158 endotoxin Substances 0.000 description 9
230000001965 increasing effect Effects 0.000 description 9
229940076144 interleukin-10 Drugs 0.000 description 9
239000000872 buffer Substances 0.000 description 8
SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 description 8
229920006008 lipopolysaccharide Polymers 0.000 description 8
239000007788 liquid Substances 0.000 description 8
230000002829 reductive effect Effects 0.000 description 8
238000000527 sonication Methods 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 7
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
230000004913 activation Effects 0.000 description 7
229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 7
-1 but not limited to Proteins 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000000839 emulsion Substances 0.000 description 7
238000005516 engineering process Methods 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
230000009467 reduction Effects 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
230000001464 adherent effect Effects 0.000 description 6
230000000975 bioactive effect Effects 0.000 description 6
244000309466 calf Species 0.000 description 6
230000005907 cancer growth Effects 0.000 description 6
238000005119 centrifugation Methods 0.000 description 6
239000012634 fragment Substances 0.000 description 6
102000039446 nucleic acids Human genes 0.000 description 6
108020004707 nucleic acids Proteins 0.000 description 6
150000007523 nucleic acids Chemical class 0.000 description 6
239000003921 oil Substances 0.000 description 6
235000019198 oils Nutrition 0.000 description 6
210000001541 thymus gland Anatomy 0.000 description 6
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
206010057248 Cell death Diseases 0.000 description 5
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 5
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 5
241000186359 Mycobacterium Species 0.000 description 5
101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 5
102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
230000002159 abnormal effect Effects 0.000 description 5
230000004663 cell proliferation Effects 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
230000009089 cytolysis Effects 0.000 description 5
229940127089 cytotoxic agent Drugs 0.000 description 5
230000003013 cytotoxicity Effects 0.000 description 5
231100000135 cytotoxicity Toxicity 0.000 description 5
239000008367 deionised water Substances 0.000 description 5
229910021641 deionized water Inorganic materials 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
238000011534 incubation Methods 0.000 description 5
230000011987 methylation Effects 0.000 description 5
238000007069 methylation reaction Methods 0.000 description 5
230000028327 secretion Effects 0.000 description 5
210000004989 spleen cell Anatomy 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
102000016911 Deoxyribonucleases Human genes 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
230000030833 cell death Effects 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
238000004945 emulsification Methods 0.000 description 4
238000004108 freeze drying Methods 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
238000002156 mixing Methods 0.000 description 4
210000000822 natural killer cell Anatomy 0.000 description 4
229940127084 other anti-cancer agent Drugs 0.000 description 4
239000002245 particle Substances 0.000 description 4
239000008188 pellet Substances 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
108091008146 restriction endonucleases Proteins 0.000 description 4
230000007017 scission Effects 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
241000894007 species Species 0.000 description 4
239000000126 substance Substances 0.000 description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
108020000946 Bacterial DNA Proteins 0.000 description 3
241000700198 Cavia Species 0.000 description 3
206010009944 Colon cancer Diseases 0.000 description 3
108010053770 Deoxyribonucleases Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
102000008070 Interferon-gamma Human genes 0.000 description 3
108010074328 Interferon-gamma Proteins 0.000 description 3
206010048723 Multiple-drug resistance Diseases 0.000 description 3
206010033128 Ovarian cancer Diseases 0.000 description 3
206010061535 Ovarian neoplasm Diseases 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
239000011543 agarose gel Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
239000006285 cell suspension Substances 0.000 description 3
239000012228 culture supernatant Substances 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
238000009826 distribution Methods 0.000 description 3
238000012869 ethanol precipitation Methods 0.000 description 3
238000000605 extraction Methods 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
239000012530 fluid Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
229960003130 interferon gamma Drugs 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
230000008506 pathogenesis Effects 0.000 description 3
210000003024 peritoneal macrophage Anatomy 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
239000013049 sediment Substances 0.000 description 3
238000005063 solubilization Methods 0.000 description 3
230000007928 solubilization Effects 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
238000003860 storage Methods 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
229960001603 tamoxifen Drugs 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
229960004528 vincristine Drugs 0.000 description 3
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
KAQXCFRYVVJPEV-UHFFFAOYSA-N 2,4-dimethyl-1,3-thiazole;1,5-diphenyl-1h-tetrazol-1-ium;bromide Chemical compound [Br-].CC1=CSC(C)=N1.C1=CC=CC=C1[NH+]1C(C=2C=CC=CC=2)=NN=N1 KAQXCFRYVVJPEV-UHFFFAOYSA-N 0.000 description 2
206010003445 Ascites Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
229940124101 Caspase 3 inhibitor Drugs 0.000 description 2
108010067770 Endopeptidase K Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000588722 Escherichia Species 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
102000016943 Muramidase Human genes 0.000 description 2
108010014251 Muramidase Proteins 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000186366 Mycobacterium bovis Species 0.000 description 2
241000187480 Mycobacterium smegmatis Species 0.000 description 2
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
238000011717 athymic nude mouse Methods 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
238000012790 confirmation Methods 0.000 description 2
239000007799 cork Substances 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000029087 digestion Effects 0.000 description 2
229940079920 digestives acid preparations Drugs 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
230000003308 immunostimulating effect Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
230000004068 intracellular signaling Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
231100000518 lethal Toxicity 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
239000003446 ligand Substances 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000002502 liposome Substances 0.000 description 2
238000000464 low-speed centrifugation Methods 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
239000004325 lysozyme Substances 0.000 description 2
229960000274 lysozyme Drugs 0.000 description 2
235000010335 lysozyme Nutrition 0.000 description 2
102000006240 membrane receptors Human genes 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
231100000324 minimal toxicity Toxicity 0.000 description 2
230000035407 negative regulation of cell proliferation Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
230000009416 procancer activity Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000012552 review Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
201000008827 tuberculosis Diseases 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
208000033399 Anaphylactic responses Diseases 0.000 description 1
102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
241000588807 Bordetella Species 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
241000282465 Canis Species 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010049993 Cardiac death Diseases 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
241000252203 Clupea harengus Species 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
241000186031 Corynebacteriaceae Species 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
230000030933 DNA methylation on cytosine Effects 0.000 description 1
108010063593 DNA modification methylase SssI Proteins 0.000 description 1
206010011906 Death Diseases 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
241000186394 Eubacterium Species 0.000 description 1
108010039471 Fas Ligand Protein Proteins 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
239000012480 LAL reagent Substances 0.000 description 1
241000186781 Listeria Species 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
241000186367 Mycobacterium avium Species 0.000 description 1
206010029113 Neovascularisation Diseases 0.000 description 1
241000187654 Nocardia Species 0.000 description 1
241000187678 Nocardia asteroides Species 0.000 description 1
108091093105 Nuclear DNA Proteins 0.000 description 1
102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
108091081548 Palindromic sequence Proteins 0.000 description 1
235000019482 Palm oil Nutrition 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
108010059712 Pronase Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
241000316848 Rhodococcus <scale insect> Species 0.000 description 1
241000187563 Rhodococcus ruber Species 0.000 description 1
MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
206010066901 Treatment failure Diseases 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229960001570 ademetionine Drugs 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
229940095564 anhydrous calcium sulfate Drugs 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
229940124650 anti-cancer therapies Drugs 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
238000011319 anticancer therapy Methods 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
230000005775 apoptotic pathway Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000009702 cancer cell proliferation Effects 0.000 description 1
239000000828 canola oil Substances 0.000 description 1
235000019519 canola oil Nutrition 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
201000003959 cecum carcinoma Diseases 0.000 description 1
230000006727 cell loss Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
208000030381 cutaneous melanoma Diseases 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000034994 death Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000002296 dynamic light scattering Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
239000011888 foil Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
230000012010 growth Effects 0.000 description 1
235000019514 herring Nutrition 0.000 description 1
102000054896 human PML Human genes 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
230000002601 intratumoral effect Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
210000003712 lysosome Anatomy 0.000 description 1
230000001868 lysosomic effect Effects 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
230000035772 mutation Effects 0.000 description 1
239000007908 nanoemulsion Substances 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
239000002077 nanosphere Substances 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
239000002540 palm oil Substances 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
208000016691 refractory malignant neoplasm Diseases 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
235000003441 saturated fatty acids Nutrition 0.000 description 1
102000014452 scavenger receptors Human genes 0.000 description 1
108010078070 scavenger receptors Proteins 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000011664 signaling Effects 0.000 description 1
201000003708 skin melanoma Diseases 0.000 description 1
MKWYFZFMAMBPQK-UHFFFAOYSA-J sodium feredetate Chemical compound [Na+].[Fe+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O MKWYFZFMAMBPQK-UHFFFAOYSA-J 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
230000008685 targeting Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
229960001005 tuberculin Drugs 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Cell Biology (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO20000576A 1997-08-05 2000-02-04 Blanding for regulering av celleproliferasjon og celledod samt anvendelse derav NO322450B1 (no)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US5477797P	1997-08-05	1997-08-05
US7511198P	1998-02-18	1998-02-18
US7506798P	1998-02-18	1998-02-18
US8631798P	1998-05-21	1998-05-21
PCT/CA1998/000744 WO1999007383A1 (en)	1997-08-05	1998-08-05	Composition and method for regulating cell proliferation and cell death

Publications (3)

Publication Number	Publication Date
NO20000576D0 NO20000576D0 (no)	2000-02-04
NO20000576L NO20000576L (no)	2000-04-04
NO322450B1 true NO322450B1 (no)	2006-10-09

Family

ID=27489673

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20000576A NO322450B1 (no)	1997-08-05	2000-02-04	Blanding for regulering av celleproliferasjon og celledod samt anvendelse derav

Country Status (17)

Country	Link
US (2)	US6329347B1 (ja)
EP (1)	EP1003525B1 (ja)
JP (2)	JP4335435B2 (ja)
KR (1)	KR100533576B1 (ja)
AT (1)	ATE227996T1 (ja)
AU (1)	AU736450B2 (ja)
BR (1)	BR9815602A (ja)
CA (1)	CA2299548C (ja)
DE (1)	DE69809561T2 (ja)
DK (1)	DK1003525T3 (ja)
ES (1)	ES2187047T3 (ja)
HU (1)	HU227921B1 (ja)
IL (3)	IL134371A0 (ja)
NO (1)	NO322450B1 (ja)
NZ (1)	NZ502674A (ja)
PT (1)	PT1003525E (ja)
WO (1)	WO1999007383A1 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6329347B1 (en)	1997-08-05	2001-12-11	Bioniche Life Sciences Inc.	Composition and method for the treatment of bladder cancer
WO1999042113A1 (en) *	1998-02-18	1999-08-26	Bioniche Life Sciences Inc.	Composition and method for the treatment of bladder cancer
NZ511941A (en) *	1998-12-04	2003-04-29	Bioniche Life Sciences Inc	Use of Mycobacterium phlei DNA in chemotherapeutic compositions
DK1135164T3 (da) *	1998-12-04	2004-12-20	Bioniche Life Sciences Inc	Sammensætning til behandling af inflammation
US6809081B1 (en)	1998-12-04	2004-10-26	Bioniche Life Sciences, Inc.	Chemotherapeutic composition and method
JP2002541114A (ja) *	1999-04-01	2002-12-03	バイオニケライフサイエンシーズインコーポレイテッド	前立腺癌の細胞におけるアポプトーシス誘導のための組成物および方法
US6794368B1 (en) *	1999-04-01	2004-09-21	Bioniche Life Sciences Inc.	Composition and method for inducing apoptosis in prostate cancer cells
AU7501700A (en) *	1999-09-29	2001-04-30	Bioniche Life Sciences Inc.	Method to disrupt mitochondrial function
DE60036019T2 (de) *	1999-12-13	2008-05-29	Bioniche Life Sciences Inc., Belleville	Synthetische oligonukleotide die therapeutisch nützlich sind
EP1250152B1 (en) *	1999-12-28	2013-05-15	Bioniche Urology IP Inc.	Synergistic composition containing hyaluronic acid in the treatment of cancer
US20030044352A1 (en) *	2001-04-24	2003-03-06	Phillips Nigel C.	Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls
US6673566B1 (en)	2002-01-10	2004-01-06	The United States Of America As Represented By The Secretary Of Agriculture	Diagnosis of pathogen infections through analysis of nitrite production by antigen stimulated leukocytes
CN101511391B (zh) *	2006-07-25	2013-03-13	利普生技术有限公司	N末端聚唾液酸化
KR20140031168A (ko)	2010-10-13	2014-03-12	바이오니취 유롤로지 아이피 인코포레이티드	세균 리보핵산 세포벽 조성물 및 이들의 제조 및 사용 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3172815A (en)	1962-04-24	1965-03-09	Warner Lambert Pharmaceutical	Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
US4152423A (en)	1971-11-19	1979-05-01	Agence Nationale De Valorisation De La Recherche (Anvar)	Immunological agents
FR2160326B1 (ja)	1971-11-19	1975-02-07	Anvar
CH602920A5 (ja)	1973-02-23	1978-08-15	Wellcome Found
US3976544A (en)	1973-06-19	1976-08-24	The Agence Nationale De Valorisation De Le Recherche	Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042A1 (fr)	1976-06-04	1978-07-13	Merieux Inst	Nouveau medicament immunostimulant et son procede de preparation
JPS54140710A (en)	1978-03-10	1979-11-01	Mitsui Toatsu Chem Inc	Anti-tumor substance and its preparation
DE3011461C2 (de)	1980-03-25	1986-10-30	Dr. Madaus & Co, 5000 Köln	Verwendung von Propionibakterien
US4520019A (en)	1982-04-29	1985-05-28	Ribi Immunochem Research, Inc.	Stable composition and preparation thereof
US4579941A (en)	1982-08-13	1986-04-01	Mitsuitoatsu Chemicals, Inc.	Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en)	1983-09-23	1987-05-05	Ribi Immunochem Research, Inc.	Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en)	1984-02-17	1984-03-21	Stanford J L	Biological preparations
US4744984A (en)	1985-10-08	1988-05-17	Vetrepharm Research, Inc.	Antiviral immunotherapeutic agent and preparation thereof
US4877611A (en)	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants
CN1102855C (zh)	1993-01-29	2003-03-12	维特里制药有限公司	免疫治疗组合物
US6329347B1 (en)	1997-08-05	2001-12-11	Bioniche Life Sciences Inc.	Composition and method for the treatment of bladder cancer

1998
- 1998-08-05 US US09/129,313 patent/US6329347B1/en not_active Expired - Lifetime
- 1998-08-05 CA CA002299548A patent/CA2299548C/en not_active Expired - Fee Related
- 1998-08-05 ES ES98938555T patent/ES2187047T3/es not_active Expired - Lifetime
- 1998-08-05 BR BR9815602-0A patent/BR9815602A/pt not_active Application Discontinuation
- 1998-08-05 NZ NZ502674A patent/NZ502674A/en not_active IP Right Cessation
- 1998-08-05 WO PCT/CA1998/000744 patent/WO1999007383A1/en active Application Filing
- 1998-08-05 AU AU87236/98A patent/AU736450B2/en not_active Ceased
- 1998-08-05 KR KR10-2000-7001237A patent/KR100533576B1/ko not_active IP Right Cessation
- 1998-08-05 HU HU0003012A patent/HU227921B1/hu not_active IP Right Cessation
- 1998-08-05 EP EP98938555A patent/EP1003525B1/en not_active Expired - Lifetime
- 1998-08-05 DE DE69809561T patent/DE69809561T2/de not_active Expired - Lifetime
- 1998-08-05 JP JP2000506973A patent/JP4335435B2/ja not_active Expired - Fee Related
- 1998-08-05 DK DK98938555T patent/DK1003525T3/da active
- 1998-08-05 PT PT98938555T patent/PT1003525E/pt unknown
- 1998-08-05 IL IL13437198A patent/IL134371A0/xx active IP Right Grant
- 1998-08-05 US US09/129,312 patent/US6326357B1/en not_active Expired - Lifetime
- 1998-08-05 AT AT98938555T patent/ATE227996T1/de active
2000
- 2000-02-03 IL IL134371A patent/IL134371A/en not_active IP Right Cessation
- 2000-02-04 NO NO20000576A patent/NO322450B1/no not_active IP Right Cessation
2007
- 2007-01-24 IL IL180924A patent/IL180924A/en not_active IP Right Cessation
2008
- 2008-05-12 JP JP2008124958A patent/JP2008208140A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
DE69809561T2 (de)	2003-09-25
JP4335435B2 (ja)	2009-09-30
WO1999007383A1 (en)	1999-02-18
EP1003525A1 (en)	2000-05-31
HU227921B1 (hu)	2012-06-28
CA2299548C (en)	2009-12-29
AU736450B2 (en)	2001-07-26
IL180924A0 (en)	2007-07-04
JP2001513504A (ja)	2001-09-04
DE69809561D1 (de)	2003-01-02
DK1003525T3 (da)	2003-03-24
BR9815602A (pt)	2001-12-11
ATE227996T1 (de)	2002-12-15
AU8723698A (en)	1999-03-01
IL134371A0 (en)	2001-04-30
HUP0003012A2 (hu)	2000-12-28
KR20010022643A (ko)	2001-03-26
IL134371A (en)	2007-07-24
IL180924A (en)	2010-11-30
CA2299548A1 (en)	1999-02-18
NO20000576D0 (no)	2000-02-04
KR100533576B1 (ko)	2005-12-05
WO1999007383B1 (en)	1999-03-25
NO20000576L (no)	2000-04-04
JP2008208140A (ja)	2008-09-11
EP1003525B1 (en)	2002-11-20
ES2187047T3 (es)	2003-05-16
NZ502674A (en)	2002-06-28
US6329347B1 (en)	2001-12-11
PT1003525E (pt)	2003-03-31
HUP0003012A3 (en)	2004-03-29
US6326357B1 (en)	2001-12-04

Publication	Publication Date	Title
JP2008208140A (ja)	2008-09-11	細胞増殖および細胞死を調節する組成物および方法
Shetab Boushehri et al.	2018	TLR4-based immunotherapeutics in cancer: a review of the achievements and shortcomings
Tincer et al.	2011	Immunostimulatory activity of polysaccharide–poly (I: C) nanoparticles
IL225718A (en)	2016-04-21	Bacterial cell wall preparations and methods for their manufacture and use
AU751667B2 (en)	2002-08-22	Composition and method for the treatment of bladder cancer
JP4380922B2 (ja)	2009-12-09	化学療法の組成物及び方法
MXPA00001272A (en)	2002-02-26	Composition and method for regulating cell proliferation and cell death
US6809081B1 (en)	2004-10-26	Chemotherapeutic composition and method
AU780909B2 (en)	2005-04-21	Composition and method for inducing apoptosis in prostate cancer cells
Khatri et al.	2022	Decoding the signaling cascaded in immunotherapy of cancer: role played by nanoimmunoadjuvants
MXPA00008142A (en)	2002-05-09	Composition and method for the treatment of bladder cancer

Legal Events

Date	Code	Title	Description
2012-07-30	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: BIONICHE UROLOGY IP INC, CA
2012-07-30	RE	Reestablishment of rights (par. 72 patents act)
2016-03-29	MM1K	Lapsed by not paying the annual fees